RxDoctor Payments Data

Thomas Hryniewicki, MD

Internal Medicine · Orange, CANPI 1992807341

Payments from drug & device makers

$8,057in general payments, 2019–2025

Across 430 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$989
  • Lilly USA, LLC$623
  • AstraZeneca$597
  • Pfizer$514
  • Boehringer Ingelheim$457
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,043100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,057 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$150,279
Medicare patients
493
Services billed
2,118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$90,016
JardianceEmpagliflozin75$84,809
JanuviaSitagliptin Phosphate60$84,179
XareltoRivaroxaban31$45,764
OzempicSemaglutide32$29,263
FarxigaDapagliflozin Propanediol21$28,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$25,116
Breo ElliptaFluticasone/Vilanterol31$18,677
GemtesaVibegron12$15,272
MyrbetriqMirabegron18$10,939
Atorvastatin Calcium880$8,940
Levothyroxine Sodium604$8,714
SynthroidLevothyroxine Sodium141$8,113
Effexor XrVenlafaxine Hcl14$7,043
Repatha SureclickEvolocumab12$6,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Effexor Xr, Premarin$514$102,811121 claims
Boehringer IngelheimJardiance$457$84,80975 claims
MerckJanuvia$226$84,17960 claims
Johnson & JohnsonXarelto$247$45,76431 claims
GSKTrelegy Ellipta, Breo Ellipta$217$43,79367 claims
AstraZenecaFarxiga, Symbicort$597$31,08434 claims
Novo NordiskOzempic$409$29,26332 claims
Sumitomo Pharma America, Inc.Gemtesa$68$15,27212 claims
Astellas Pharma US IncMyrbetriq$214$10,93918 claims
AbbVieSynthroid$1,017$8,113141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →